Gufic Biosciences: Tax Demand Reduced to ₹11.76 Lakhs, Penalty ₹23.52 Lakhs
Gufic Biosciences' tax demand for AY 2023-24 reduced from ₹11.89 Crore to ₹11.76 Lakhs. A penalty of ₹23.52 Lakhs was levied. The company is evaluating the order and plans to appeal, expecting a favorable outcome.
While a penalty has been levied, the substantial reduction in the original tax demand to ₹11.76 Lakhs limits the immediate financial impact on the company.
The tax demand has been significantly reduced, which is positive. However, a penalty has been levied, and the company is still evaluating the order and considering further appeals, indicating ongoing uncertainty.
Gufic Biosciences Limited has received an order from the Income Tax Department regarding an assessment for the Assessment Year 2023-24. Initially, a tax demand of ₹11,88,88,580 was raised. Following an appeal, this demand has been substantially reduced to ₹11,76,198.
Additionally, a penalty of ₹23,52,396 has been levied under Section 270A(9) of the Income Tax Act due to under-reported income. The company is currently evaluating this order with its tax consultants and plans to take appropriate steps, including filing further appeals if deemed necessary, with the Commissioner of Income Tax (Appeals). The company is hopeful of a favorable outcome.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.